Laboratorios Ordesa enters the pediatric dermatology market Blog Post

Laboratorios Ordesa, with a history of over 70 leading child nutrition, has now entered the dermatology market with the marketing of Pediatopic, a new product line for the care of atopic skin in children. Since 2007, Ordesa has had a R&D&I center at  Parc Científic de Barcelona (PCB) from where the company actively takes part in clinical trials and national and international research programs to enhance the health and quality of life of individuals, especially during the maternal and child stage of life. 

 

UL Acquires AWS Truepower to expand global renewable energy portfolio Blog Post

UL (Underwriters Laboratories), a global safety science leader, announces the acquisition of  AWS Truepower, a leading energy engineering services and advisory firm. This achievement expands UL’s global renewable energy portfolio by strengthening full lifecycle solutions for wind and solar energy sectors. AWS Truepower operates in Europe and Latin America through AWS Truepower SLU, a spanish company located at the Barcelona Scientific Park (PCB).

 

Half of patients with type 2 diabetes do not have their disease under control Blog Post

Therapeutic compliance in type 2 diabetes mellitus (DM2) is crucial. However, only 30%-50% of patients receiving oral antidiabetics, and not even 25% of those receiving insulin adhere to their treatment regimen1. The worst compliers are younger patients who, moreover, are at greater risk of developing cardiovascular complications. This was the claim of the specialists who attended Diabento, a symposium organized by Esteve, of more than 450 physicians from all around Spain who analyzed current and future challenges in DM2 from a multidisciplinary perspective. Esteve and PCB have been working closely since 2003.

 

Broad participation of Barcelona Science Park at BioSpain 2016 Blog Post

The Bilbao Exhibition Center (BEC) in Barakaldo (Bizkaia) will host  BioSpain 2016, the 8th edition of the eighth edition of this biennial event of biotechnology, the largest in Europe with permanent headquarters in one country and the fifth in the world ranking by number of partnering meetings. The event, to be held from 28 to 30 September, will bring together more than 2,000 attendees, 855 companies and nearly 50 investors- and will feature the participation of the Barcelona Science Park (PCB) and a large number of companies and entities of the PCB Community.

 

The genetic history of Aboriginal Australians Blog Post

The CNAG, based at Barcelona Science Park, participates in a study that analyses the genome of the Aboriginal Australian population that will help to understand how modern humans left the African continent. The findings of this study are published in Nature. The CNAG reseacher Òscar Lao, leader of the Population Genomics team, is first co-author of this work and contributed to the study analysing and interpreting the sub-populations of Aboriginal Australians. The debate over whether anatomically modern humans left the African continent in one or several waves is very intense in this Nature edition.

 

IRB Barcelona presents the “Alumni of Excellence Award” to David Vilchez Blog Post

Today the Institute for Research in Biomedicine (IRB Barcelonahas presented David Vilchez, group leader at the CECAD-Cluster of Excellence in Cologne, Germany, with a commemorative certificate naming him as the first winner of the Alumni of Excellence Award. Vilchez obtained his PhD from IRB Barcelona in 2008, and three years ago he began his own group in Germany, where he has been awarded an ERC Starting Grant.

 

New strategy to obtain a specific type of amyloid-beta aggregate that may underlie neuronal death in Alzheimer’s disease Blog Post

Scientists from the Institute for Research in Biomedicine (IRB Barcelona) at Barcelona Science Park (PCB), in collaboration with researchers at Scientific and Technological Centers of the University of Barcelona (CCiTUB), the University of Leuven (Belgium) and the University of Groningen (the Netherlands), and the the, describes for the first time how to prepare a specific type of aggregate of the amyloid-beta protein with the ability to perforate the cell membrane. Interpreted in the context of Alzheimer´s disease, this discovery suggests that the aggregate can also perforate the membrane of neurons, alter the equilibrium of these cells, and trigger their death.

 

Cells move en masse towards rigid tissues Blog Post

In a study published today in the journal Science, researchers at IBEC, based at PCB, have shown that several types of cells are attracted to the most rigid areas of tissues. The discovery contradicts the traditional view that cell movement is guided primarily by variations in the chemical concentration of proteins and ions. The new phenomenon, collective durotaxis, opens new avenues to control tumor growth and improve wound healing.